ASND
Ascendis Pharma A/S
Stock
$227.87+0.56 (+0.25%)Close Oct 2, 2026
Income statement
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €720M | €364M | €267M | €51M | €7.8M | €7.0M | €13M | €11M | €1.5M | €4.6M | €8.1M |
| Cost of revenue | €95M | €44M | €44M | €12M | €3.5M | €0 | €0 | — | — | — | — |
| Gross profit | €625M | €319M | €222M | €39M | €4.3M | €7.0M | €13M | — | — | — | — |
| R&D | €304M | €307M | €413M | €380M | €296M | €261M | €192M | €140M | €100M | €66M | €41M |
| SG&A | €458M | €291M | €264M | €221M | €160M | €77M | €48M | €25M | €13M | €12M | €9.4M |
| Operating income | −€136M | −€279M | −€456M | −€562M | −€452M | −€331M | −€227M | −€155M | −€112M | −€73M | −€42M |
| Non-operating income | −€76M | −€94M | −€19M | −€16M | €68M | −€89M | €8.5M | €24M | −€13M | €4.2M | €8.3M |
| Pretax income | −€213M | −€373M | −€474M | −€578M | −€384M | −€419M | −€218M | −€130M | −€124M | −€69M | −€34M |
| Taxes | €15M | €4.8M | €7.3M | €5.4M | −€367K | −€219K | −€234K | −€394K | −€477K | −€227K | −€652K |
| Net income | −€228M | −€378M | −€481M | −€583M | −€384M | −€419M | −€218M | −€130M | −€124M | −€69M | −€33M |
| Diluted EPS | −€3.76 | −€6.53 | −€8.55 | −€10.40 | −€7.00 | −€8.28 | −€4.69 | −€3.17 | −€3.68 | −€2.58 | −€1.39 |
| Diluted shares | 60.6M | 57.9M | 56.3M | 56.1M | 54.8M | 50.6M | 46.5M | 41.1M | 33.6M | 26.6M | 23.8M |
| Revenue growth | +98.0% | +36.3% | +421.2% | +557.9% | +11.9% | −48.0% | +26.4% | +591.6% | −66.8% | −43.3% | — |
| Gross margin | 86.8% | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% | 100.0% | — | — | — | — |
| Operating margin | −18.9% | −76.7% | −170.8% | −1,097.9% | −5,808.6% | −4,755.1% | −1,695.1% | −1,462.6% | −7,290.3% | −1,583.2% | −515.2% |
| Net margin | −31.7% | −104.0% | −180.5% | −1,139.6% | −4,931.6% | −6,025.5% | −1,630.0% | −1,229.5% | −8,097.8% | −1,487.3% | −405.5% |